Antipsychotics are the standard of care for treating schizophrenia, with oral atypical antipsychotics (e.g., olanzapine, risperidone) experiencing preferential use. Because of the heterogeneity of schizophrenia and patients' varied response to antipsychotics, the treatment of the disease is highly individualized and psychiatrists consider multiple factors (e.g., tolerability, compliance) when making treatment choices. As a result, both depot and oral formulations of antipsychotics are prescribed by EU5 psychiatrists, such as the branded depot atypical antipsychotics Abilify Maintena, Risperdal Consta, Trevicta, and Xeplion. Given the highly crowded and competitive schizophrenia landscape, it is necessary for marketers of current branded therapies, as well as developers of emerging schizophrenia therapies, to understand the many decision points and challenges psychiatrists face when treating this disease. The Current Treatment EU5 content provides a detailed snapshot of how EU5 psychiatrists are managing their patients with schizophrenia, including the use of atypical and typical antipsychotics, as well as insight into the factors driving such prescribing habits.

Questions answered

  • Prompt treatment of schizophrenia is recommended due to the negative impact of symptoms on a patient’s quality of life. How quickly do psychiatrists initiate their schizophrenia patients on pharmacotherapies and what percentage of patients are drug treated? Do treatment rates differ across the EU5 countries?
  • Even though generically available oral atypical antipsychotics dominate the EU5 market, depot oral atypical antipsychotics also experience use within the schizophrenia treatment paradigm. What is the patient share for individual antipsychotics, including the branded oral therapies Invega and Latuda? How are depots, such as Abilify Maintena, currently being used by psychiatrists? How does treatment differ across each line of therapy?
  • Given that schizophrenia treatment is highly individualized, psychiatrists may consider multiple factors when initiating pharmacotherapies. What are the most important clinical and nonclinical factors that drive prescribing of antipsychotics? What drives switching to and from specific brands? What obstacles constrain use of branded therapies?
  • CIAS and negative symptoms are not as frequently diagnosed as positive symptoms; however, these two symptom domains greatly hinder schizophrenia patients’ QOL. What percentage of patients in each of the EU5 countries presents with CIAS, and/or negative symptoms? How are physicians currently managing these patients?
  • Scope:
    • Markets covered: EU5 (France, Germany, Italy, Spain, and the United Kingdom)
    • Methodology: Survey of 257 psychiatrists in the EU5 (56 in France, 50 in Germany, 50 in Italy, 51 in Spain, and 50 in the United Kingdom), completed in January 2017
    • Indication coverage: Schizophrenia
    • Key drugs covered: aripiprazole, Abilify Maintena, haloperidol, Invega, Latuda, olanzapine, Risperdal Consta, Trevicta, Xeplion, Zypadhera
    • Key companies mentioned: AstraZeneca, Eli Lily, Ferrer International, Janssen, Johnson & Johnson, Lundbeck, Otsuka Pharmaceutical, and Sumitomo Dainippon Pharma

Table of contents

  • Schizophrenia - Current Treatment - Detailed, Expanded Analysis (EU)

Author(s): Lisa Cloonan, BA; Emma McFadden, PhD

Lisa joined Decision Resources Group in 2015 as a business insights analyst for the Central Nervous System and Ophthalmology division. In this role, she analyzes the commercial opportunities for pharmacological therapies across the psychiatry space.

Prior to joining Decision Resources Group, Lisa spent 6 years in clinical stroke research at Massachusetts General Hospital. While in the clinical research field, Lisa developed an expertise in neuroimaging analysis, as well as authored and co-authored articles on the influence of white matter hyperintensity burden on stroke risk and recovery. Lisa holds bachelor of arts from Connecticut College, where her course work focused on behavioral neuroscience.

Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy. 

Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.

 


Related Reports

Schizophrenia - Special Topics - Special Topics Evolving Market Dynamics In Schizophrenia US

The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primaril...

View Details

Schizophrenia - Special Topics - Special Topics: Agitation In Bipolar And Schizophrenia (US)

Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or...

View Details

Schizophrenia - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Schizophrenia is an often disabling psychiatric disease that usually requires long-term treatment. The primary goals of medical treatment for schizophrenia are to reduce the frequency and severity...

View Details

Schizophrenia - Unmet Need - Detailed, Expanded Analysis (Cognitive Impairment)

Although the schizophrenia drug market is crowded, no pharmacological agents are approved specifically to treat cognitive impairment associated with schizophrenia (

View Details